Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT03194932
- Locations
- đşđ¸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
đşđ¸Lucille Packard Children's Hospital Stanford University, Palo Alto, California, United States
đşđ¸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Combination Product: ITMHABiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- đşđ¸
Rady Children's Hospital and Health Center, San Diego, California, United States
đşđ¸Children's Hospital of Central California, Madera, California, United States
đşđ¸Children's Hospital of Orange County, Orange, California, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Acute Lymphoblastic LeukemiaAcute Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- đşđ¸
Children's Hospital of Michigan, Detroit, Michigan, United States
đşđ¸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
đŚđşThe Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-03-22
- Target Recruit Count
- 60
- Registration Number
- NCT02937662
- Locations
- đ¨đł
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
- Conditions
- AML
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02905994
- Locations
- đşđ¸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
đşđ¸Massachusetts general Hospital, Boston, Massachusetts, United States
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- Procedure: Cranial irradiationProcedure: Stem cell transplantation
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1000
- Registration Number
- NCT02881086
- Locations
- đŠđŞ
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 75
- Registration Number
- NCT02873338
- Locations
- đşđ¸
Franciscan St. Francis Health, Indianapolis, Indiana, United States
đşđ¸Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center, Dallas, Texas, United States
đşđ¸University of Cincinnati, Cincinnati, Ohio, United States
Optimal Treatment Strategy Based on for Pediatric AML
- Conditions
- Pediatric Acute Myeloid Leukemia
- Interventions
- Procedure: Hematopoietic stem cell transplantation
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 350
- Registration Number
- NCT02848183
- Locations
- đ°đˇ
Chonnam National University Hwasun Hospital, Chonnam, Korea, Republic of
đ°đˇSt. Mary Hospital, Seoul, Korea, Republic of
đ°đˇSamsung Medical Center, Seoul, Korea, Republic of
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT02835729
- Locations
- đşđ¸
Augusta University, Augusta, Georgia, United States
đşđ¸University of Maryland, Baltimore, Maryland, United States
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02834390
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.